141 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp02231 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 65 µM |
| dbacp02232 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | IC50 : 60 µM |
| dbacp02233 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | Jurkat | Blood cancer | IC50 : 30 µM |
| dbacp02234 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 44 µM |
| dbacp02235 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 15.8 µM |
| dbacp02236 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 16.1 µM |
| dbacp02237 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 15.8 µM |
| dbacp02241 | CA-MA1 | KWKLFKKIKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 85.3 µM |
| dbacp02242 | CA-MA1 | KWKLFKKIKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | IC50 : 100 µM |
| dbacp02243 | CA-MA1 | KWKLFKKIKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | Jurkat | Blood cancer | IC50 : 65 µM |
| dbacp02244 | CA-MA1 | KWKLFKKIKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 100 µM |
| dbacp02245 | CA-MA2 | KWKLFKKIPKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 35.1 µM |
| dbacp02246 | CA-MA2 | KWKLFKKIPKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | IC50 : 25 µM |
| dbacp02247 | CA-MA2 | KWKLFKKIPKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | Jurkat | Blood cancer | IC50 : 20 µM |
| dbacp02248 | CA-MA2 | KWKLFKKIPKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : 28 µM |
| dbacp02249 | CA-MA3 | KWKLFKKIGPGKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : >100 µM |
| dbacp02250 | CA-MA3 | KWKLFKKIGPGKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | A-549 | Lung cancer | IC50 : >100 µM |
| dbacp02251 | CA-MA3 | KWKLFKKIGPGKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | Jurkat | Blood cancer | IC50 : 75 µM |
| dbacp02252 | CA-MA3 | KWKLFKKIGPGKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | MDA-MB-361 | Breast cancer | IC50 : >100 µM |
| dbacp02253 | CA-ME | KWKLFKKIGIGAVLKVLTTG | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 32.2 µM |
| dbacp02254 | CA-ME | KWKLFKKIGIGAVLKVLTTG | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 28.6 µM |
| dbacp02255 | CA-ME | KWKLFKKIGIGAVLKVLTTG | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 28.6 µM |
| dbacp04476 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Membrane disruption | WST-1 assay | HeLa | Pancreatic cancer | IC50 : > 60 µM |
| dbacp04477 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Membrane perforation | LDH leakage assay | RT4(G1) | Bladder cancer | IC50 : 32.3 µM |
| dbacp04478 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Membrane perforation | LDH leakage assay | 647V(G2) | Bladder cancer | IC50 : 54.1 µM |
| dbacp04479 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Membrane perforation | LDH leakage assay | 486P(G4) | Bladder cancer | IC50 : 28.6 µM |
| dbacp04480 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Membrane perforation | WST-1 assay | RT4(G1) | Bladder cancer | IC50 : 484 µM |
| dbacp04481 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Membrane perforation | WST-1 assay | 647V(G2) | Bladder cancer | IC50 : 52.4 µM |
| dbacp04482 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Membrane perforation | WST-1 assay | 486P(G4) | Bladder cancer | IC50 : 57.8 µM |
| dbacp04483 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Membrane perforation | Cell viability assay | RT4(G1) | Bladder cancer | IC50 : 135.3 µM |
| dbacp04484 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Membrane perforation | Cell viability assay | 647V(G2) | Bladder cancer | IC50 : 31 µM |
| dbacp04485 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Membrane perforation | Cell viability assay | 486P(G4) | Bladder cancer | IC50 : 59.4 µM |
| dbacp04486 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Not specified | MTT/MTS assay | A-549 | Lung cancer | IC50 : 110 µM |
| dbacp04487 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : >150 µg/ml |
| dbacp04488 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : >150 µg/ml |
| dbacp04489 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | SSKT-1 | Hematopoietic cancer | IC50 : >150 µg/ml |
| dbacp04490 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Colon cancer | IC50 : >150 µg/ml |
| dbacp04491 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : >150 µg/ml |
| dbacp04492 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : >150 µg/ml |
| dbacp04493 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : >150 µg/ml |
| dbacp04494 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | CHP-100 | Ewing sarcoma | IC50 : >200 µg/ml |
| dbacp04495 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | IC50 : >200 µg/ml |
| dbacp04496 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : >200 µg/ml |
| dbacp04498 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | Skin; Stomach, African clawed frog, Africa | Membrane disruption | Not specified | Not found | Not found | Not found |
| dbacp04499 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H182 | Lung cancer | IC50 : 7.28 µM |
| dbacp04500 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H526 | Lung cancer | IC50 : 11.7 µM |
| dbacp04501 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H678 | Lung cancer | IC50 : 6.23 µM |
| dbacp04502 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H735 | Lung cancer | IC50 : 10.4 µM |
| dbacp04503 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H841 | Lung cancer | IC50 : 9.7 µM |
| dbacp04504 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H889 | Lung cancer | IC50 : 6.56 µM |
| dbacp04505 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 16 µg/ml |
| dbacp04506 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 18 µg/ml |
| dbacp04507 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | SSKT-1 | Hematopoietic cancer | IC50 : 23 µg/ml |
| dbacp04508 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Lung cancer | IC50 : 30 µg/ml |
| dbacp04509 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 34 µg/ml |
| dbacp04510 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 20 µg/ml |
| dbacp04511 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : 40 µg/ml |
| dbacp04512 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | CHP-100 | Ewing sarcoma | IC50 : 45 µg/ml |
| dbacp04513 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | IC50 : 49 µg/ml |
| dbacp04514 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : 53 µg/ml |
| dbacp04515 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 17 µg/ml |
| dbacp04516 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 12 µg/ml |
| dbacp04517 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | SSKT-1 | Hematopoietic cancer | IC50 : 27 µg/ml |
| dbacp04518 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Ovarian cancer | IC50 : 28 µg/ml |
| dbacp04519 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 30 µg/ml |
| dbacp04520 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 23 µg/ml |
| dbacp04521 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : 32 µg/ml |
| dbacp04522 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | CHP-100 | Ewing sarcoma | IC50 : 32 µg/ml |
| dbacp04523 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | IC50 : 37 µg/ml |
| dbacp04524 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : 41 µg/ml |
| dbacp04525 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H182 | Lung cancer | IC50 : 12.5 µM |
| dbacp04526 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H526 | Lung cancer | IC50 : 10.5 µM |
| dbacp04527 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H678 | Lung cancer | IC50 : 4.44 µM |
| dbacp04528 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H735 | Lung cancer | IC50 : 7.23 µM |
| dbacp04529 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H841 | Lung cancer | IC50 : 11.7 µM |
| dbacp04530 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Not specified | MTT/MTS assay | NCI-H889 | Lung cancer | IC50 : 6.57 µM |
| dbacp04531 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 19 µg/ml |
| dbacp04532 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 16 µg/ml |
| dbacp04533 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | SSKT-1 | Hematopoietic cancer | IC50 : 29 µg/ml |
| dbacp04534 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Renal cancer | IC50 : 38 µg/ml |
| dbacp04535 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 33 µg/ml |
| dbacp04536 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 25 µg/ml |
| dbacp04537 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 :37 µg/ml |
| dbacp04538 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | CHP-100 | Ewing sarcoma | IC50 : 39 µg/ml |
| dbacp04539 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | IC50 : 42 µg/ml |
| dbacp04540 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : 47 µg/ml |
| dbacp04711 | MSI-136 | GIGKFLKKAKKFAKAFVKIINN | African clawed frog | Not specified | MTT/MTS assay | A-549 | Lung cancer | IC50 : 10 µM |
| dbacp04712 | MSI-238 | gigkflkkakkfakafvkiinn | African clawed frog | Not specified | MTT/MTS assay | A-549 | Lung cancer | IC50 : 6 µM |
| dbacp05032 | P1 | KWKLFKKIGIGAVLKVLKKG | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 :3.4 µM |
| dbacp05033 | P1 | KWKLFKKIGIGAVLKVLKKG | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 :3.5 µM |
| dbacp05034 | P1 | KWKLFKKIGIGAVLKVLKKG | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 :4.5 µM |
| dbacp05052 | P2 | KWKLFKKIGIGKFLHSATTF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 36.2 µM |
| dbacp05053 | P2 | KWKLFKKIGIGKFLHSATTF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 37.9 µM |
| dbacp05054 | P2 | KWKLFKKIGIGKFLHSATTF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 47.7 µM |
| dbacp05058 | P3 | KWKLFKKIGIGAFLHSAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 9.3 µM |
| dbacp05059 | P3 | KWKLFKKIGIGAFLHSAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 9.3 µM |
| dbacp05060 | P3 | KWKLFKKIGIGAFLHSAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 10.9 µM |
| dbacp05072 | P4 | KWKLFKKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 1.9 µM |
| dbacp05073 | P4 | KWKLFKKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 1.3 µM |
| dbacp05074 | P4 | KWKLFKKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 2.8 µM |
| dbacp05075 | P5 | KWKLFKKIGIGAFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 2.9 µM |
| dbacp05076 | P5 | KWKLFKKIGIGAFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 2.9 µM |
| dbacp05077 | P5 | KWKLFKKIGIGAFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 3.2 µM |
| dbacp05086 | P6 | KWKLFKKIGIGKFKLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 1.7 µM |
| dbacp05087 | P6 | KWKLFKKIGIGKFKLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 2 µM |
| dbacp05088 | P6 | KWKLFKKIGIGKFKLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 3.1 µM |
| dbacp05095 | P7 | KWKLFAKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 3.1 µM |
| dbacp05096 | P7 | KWKLFAKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 2.4 µM |
| dbacp05097 | P7 | KWKLFAKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 2.4 µM |
| dbacp05099 | P8 | KWKKFLKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis | MTT/MTS assay | NCI-H69 | Lung cancer | IC50 : 2.6 µM |
| dbacp05100 | P8 | KWKKFLKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H128 | Lung cancer | IC50 : 2.3 µM |
| dbacp05101 | P8 | KWKKFLKIGIGKFLHLAKKF | Ceropin A-African clawed frog | Apoptosis inducing | MTT/MTS assay | NCI-H146 | Lung cancer | IC50 : 1.8 µM |
| dbacp05484 | Pexiganan | GIGKFLKKAKKFGKAFVKILKK | Analog of African clawed frog | Plasma membrane perturbations | MTT/MTS assay | MCF-7 | Breast cancer | LC50 : 8 at 100 µM |
| dbacp05485 | Pexiganan | GIGKFLKKAKKFGKAFVKILKK | Analog of African clawed frog | Plasma membrane perturbations | MTT/MTS assay | LNCaP | Prostate cancer | LC50 : 6 at 100 µM |
| dbacp05486 | Pexiganan | GIGKFLKKAKKFGKAFVKILKK | Analog of African clawed frog | Plasma membrane perturbations | MTT/MTS assay | OVRCAR-3 | Ovarian cancer | LC50 : 13 at 100 µM |
| dbacp05488 | Pexiganan MSI-78 | GIGKFLKKAKKFGKAFVKILKK | Analog of African clawed frog | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-941 | Lymphoma cancer | IC50 : 20-30 µg/ml |
| dbacp06075 | Shiva-1 | MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG | African clawed frog | Pore formation at the cytoplasmic membrane | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 28.7 µM |
| dbacp06076 | Shiva-1 | MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG | African clawed frog | Pore formation at the cytoplasmic membrane | MTT/MTS assay | BTS-30 | Breast cancer | IC50 : 56 µM |
| dbacp06077 | Shiva-1 | MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG | African clawed frog | Pore formation at the cytoplasmic membrane | MTT/MTS assay | HRT-18 | Colon cancer | IC50 : 49.3 µM |
| dbacp06078 | Shiva-1 | MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG | African clawed frog | Pore formation at the cytoplasmic membrane | MTT/MTS assay | DLD-1 | Colon cancer | IC50 : >100 µM |
| dbacp06543 | XLAsp-P1 | DEDDD | Skin, African clawed frog, Africa | Destruction of the cell membrane | MTT assay | MCF-7 cells | Breast cancer | LC50 : < 5 μg/mL |
| dbacp06557 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 123 µg/ml |
| dbacp06558 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 83 µg/ml |
| dbacp06559 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | SSKT-1 | Hematopoietic cancer | IC50 : 109 µg/ml |
| dbacp06560 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Leukemia cancer | IC50 : 143 µg/ml |
| dbacp06561 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 102 µg/ml |
| dbacp06562 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 72 µg/ml |
| dbacp06563 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : 112 µg/ml |
| dbacp06564 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | CHP-100 | Ewing sarcoma | Not found |
| dbacp06565 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | Not found |
| dbacp06566 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | Not found |
| dbacp06573 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 97 µg/ml |
| dbacp06574 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 60 µg/ml |
| dbacp06575 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | SSKT-1 | Hematopoietic cancer | IC50 : 107 µg/ml |
| dbacp06576 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Brain tumor | IC50 : 115 µg/ml |
| dbacp06577 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 80 µg/ml |
| dbacp06578 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 64 µg/ml |
| dbacp06579 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : 98 µg/ml |
| dbacp06580 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | CHP-100 | Ewing sarcoma | Not found |
| dbacp06581 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | MCF-7 | Breast cancer | Not found |
| dbacp06582 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | Not found |